Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/2/2025

Migraine Prevention and Treatment

First-Line Treatments

  • The American College of Cardiology and other guideline societies recommend candesartan or telmisartan as first-line treatments for migraine prevention, with strong evidence supporting their use 1, 2
  • The American College of Cardiology and other guideline societies also recommend CGRP monoclonal antibodies (erenumab, fremanezumab, or galcanezumab) as first-line treatments for migraine prevention, with strong evidence supporting their use 1, 3

Second-Line Treatments

  • The American College of Cardiology and other guideline societies recommend topiramate as a second-line treatment for migraine prevention, with moderate evidence supporting its use 1, 3
  • The American College of Cardiology and other guideline societies also recommend beta-blockers (propranolol or metoprolol) as second-line treatments for migraine prevention, with moderate evidence supporting their use 1, 3
  • The American College of Cardiology and other guideline societies recommend valproate as a second-line treatment for migraine prevention, with moderate evidence supporting its use, although it should be used with caution in women of childbearing potential 1
  • The American College of Cardiology and other guideline societies also recommend lisinopril as a second-line treatment for migraine prevention, with moderate evidence supporting its use 1

Later-Line Treatments

  • The VA/DoD Clinical Practice Guideline states that there is insufficient evidence to recommend for or against rimegepant for the prevention of episodic migraine, placing it lower in the treatment hierarchy compared to medications with stronger recommendations 1
  • Rimegepant 75mg every other day may be considered as a later treatment option for migraine prevention after failure of first and second-line treatments, with some evidence supporting its use 1

Treatment Efficacy and Safety

  • Rimegepant has been shown to reduce monthly migraine days by 4.3 days compared to 3.5 days for placebo, with 49.1% of patients achieving a 50% reduction in moderate-to-severe monthly migraine days, although the evidence is not strong enough to support its use as a first-line treatment 1